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Abstract The aim of this study was to assess the effect of
sibutramine on mineral status and selected biochemical
parameters in obese women. The study was conducted on
24 patients who received 15 mg daily doses of sibutramine
for 12 weeks, and on 20 patients who received placebo. At
the baseline, after the sixth and twelfth weeks of treatment,
body weight and blood pressure were measured, the BMI
was calculated, and samples of blood and of first morning
urine were collected. Serum lipid profiles, glucose levels,
and nitric oxide levels were determined. The iron (Fe),
copper (Cu), zinc (Zn), calcium (Ca), and magnesium
(Mg) present in the serum and urine samples were assessed.
The erythrocyte hemolysate of the patients was use to assay
the activity of glutathione peroxidase (GSH-Px) and super-
oxide dismutase (SOD). No changes were observed in BMI,
blood pressure, or nitric oxide during the study. After
12 weeks of treatment, a decrease was observed in total
cholesterol, LDL cholesterol, triglyceride, glucose, and fer-
ritin levels. GSH-Px and SOD activity increased after
12 weeks of sibutramine treatment. The Mg and Cu
increases was observed in serum after the sixth and twelfth
weeks of treatment. It was found that the Zn level decreased
in serum after the twelfth week. The elimination of Ca, Mg,
Fe, Zn, and Cu in urine also declined in the twelfth week.
No differences were found in the women taking the placebo.
In conclusion, we found that sibutramine had a positive
effect on lipid and glucose status in obese women. However,
the drug disturbed the balance of minerals, especially Zn
and Mg, in the subjects.
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Introduction
The prevalence of obesity and its comorbidities has been
increasing all over the world. Abdominal or visceral obesity
is closely related to disturbances in lipid and glucose status,
and also to a lower antioxidative status in the body [1].
Weight loss reduces the cardiovascular risks associated with
obesity [2]. The treatment of obesity should be individually
tailored and should be maintained for a long term. The first
line of strategy for weight loss is a combination of diet,
physical activity, and behavior modification. Anti-obesity
drugs may be used in adult patients when dietary and life-
style modifications have been unsuccessful.
For a long time, sibutramine was used as an effective
anti-obesity drug in Europe, but because of the cardiovas-
cular risk associated with it, European regulators suspended
its market authorization, and the US Food and Drug Ad-
ministration restricted its license. This study was conducted
a few months before the withdrawal of sibutramine’s li-
cense. Over the years, the effectiveness and side effects of
sibutramine have been assessed in many studies. Subse-
quent studies have shown that the drug has a significant
effect on weight loss, due to its satietogenic and calorigenic
effects [3]. It also improved glycemic and lipid profile and
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uric acid, and for this reason, it was often recommended in
diet and lifestyle advice [4]. Svacina et al. [5] documented
the positive effect of a 3-month sibutramine treatment on
dyslipidemia in the obese, even in those already being
treated with statins. In studies with hypertensive subjects
whose blood pressure was adequately controlled by antihy-
pertensive drugs, a slight to significant decrease in systolic
and diastolic blood pressure was observed with sibutramine
use [6]. Moreover, Derosa et al. [7] found that sibutramine
plus L-carnitine gave a greater improvement in body weight
loss and glycemic and lipid profile compared to sibutramine
alone. Sibutramine therapy has been associated with signif-
icant C-reactive protein reduction as compared with routine
treatment in patients with coronary artery disease. Thus,
short-term (4 months) therapy with sibutramine, together
with diet and lifestyle modifications, was associated with
improved endothelial function [8] but did not affect TNF-
alpha [9]. In our previous unpublished research, we ob-
served a considerable decrease in ferritin and Zn concentra-
tion in the serum of patient undergoing treatment with
sibutramine. A review of the literature on the topic showed
that there was limited data on the effects of sibutramine on
mineral balance in obese women. The aim of this study was
thus to assess the effect of sibutramine on mineral status and
on selected biochemical parameters in obese women.
Material and Methods
Study Design
The study was conducted at the Department of Internal Dis-
eases, Metabolic Disorders, and Arterial Hypertension,
Poznan University of Medical Sciences (Poland), and at the
Department of Human Nutrition and Hygiene, Poznan Uni-
versity of Life Sciences (Poland). The study protocol was
approved by Bioethics Commission at Poznan University of
Medical Sciences (approval no. 86/09).
Patients
In the Clinic of the Department of Internal Diseases, Meta-
bolic Disorders, and Hypertension in Poznan, we treated
obese patients with sibutramine. During the biochemical
studies carried out in women taking sibutramine, we ob-
served a considerable decrease in ferritin and Zn concentra-
tion in serum. In addition, these women often complained
about the brittleness of their nails and hair and of taste
disorders, which may have been due to low concentrations
of Zn in their bodies. This imbalance of mineral status,
apparently due to the use of sibutramine, was disturbing,
especially when it is known that an appropriate level of
minerals, particularly of Ca and Fe, is very important for
the health of women of childbearing age. We thus decided to
conduct a study accessing the effect of sibutramine on mineral
status in obese women.
The study was conducted on 44 obese women (body
mass index [BMI]≥30 kg/m2) aged 40.6±12.1 years. Indi-
viduals suffering from chronic disease or using any medi-
cations (including OTC products, with the exception of five
women who took oral contraceptives) were excluded. For at
least 3 months before the study, all women have remained
on a controlled-energy diet (with nearly 500 kcal daily
deficit) that took 58 % of its calories from carbohydrates,
27 % from fat, and 15 % from proteins, with a maximum
cholesterol content of 300 mg/day and 35 g/day of fiber.
Standard dietary advice was given by a qualified dieti-
tian. Subjects did not change their diet during the study
and were asked to restrain from smoking for the time of
the study.
Women who were pregnant, breastfeeding, or capable of
becoming pregnant were excluded. All subjects were in-
formed about the study’s purpose, protocol, and risks. All
individuals provided informed written consent.
Treatment and Assessment
Twenty-four patients aged 40.6±12.1 were assigned to re-
ceive sibutramine 15 mg once daily for 12 weeks, while 20
patients aged 40.7±12.2 received placebos containing pure
microcrystalline cellulose. Before the beginning of the
study, all patients underwent a full physical examination.
Anthropometric measurements of the subjects wearing light
clothing and no shoes were conducted. Weight wasmeasured
to the nearest 0.1 kg, and height to the nearest 0.1 cm. The
BMI was calculated by dividing the weight (kg) by the height
squared (m2). Obesity was defined as BMI≥30 kg/m2.
Blood pressure was measured according to the guidelines
of the European Society of Hypertension using a digital
electronic tensiometer (model 705IT, Omron Corporation,
Kyoto, Japan). Regular or large adult cuffs were used,
depending on the patient’s arm circumference. The measure-
ments were taken while fasting in the morning hours in a
sitting position, with the legs uncrossed, the back and arms
supported. Hypertension was defined by measurement of
arterial blood pressure as the average of three measurements
obtained after 10 min of physical resting (3 times at 2 different
visits).
All participants had blood collected from a forearm vein
in serum-separated tubes (without using an anticoagulant).
The coagulated blood was left to clot at room temperature
for 30 min, and then centrifuged for 15 min at 2,000 rpm at
4°C. Then the supernatant fluid was separated. Serum sam-
ples were stored at −20°C for no longer than 2–3 days.
Blood samples were collected after an overnight fast, and
after 30 min in the supine position.
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Measurements of total cholesterol (TC), high density
lipoproteins (HDL-C), low density lipoproteins (LDL-C),
triglycerides (TG), and glucose were performed on each
blood sample. Prior to the Fe, Cu, and Zn serum con-
centration assays, the serum was diluted with triton
X-100 (Merck), and before the Ca and Mg concentra-
tion assays, the serum was diluted with triton and LaCl3
(Merck).
Urine was collected in the morning, following an over-
night fast. Morning urine samples were collected in steril-
ized vessels and stored for material analysis.
The samples of urine were mineralized in a mixture of
concentrated nitric (65 %) and perchloric (60 %) acids
(suprapure, Merck; v/v, 1:1) in a microwave oven (Mile-
stone), and dissolved (v/v, 1:1) in Triton X-100 (Merck; all
minerals) and LaCl3 (Merck; Ca and Mg).
After the sixth and twelfth weeks of treatment, weight
and blood pressure were measured, BMI was calculated, and
the blood samples and first morning urine were collected
from all patients. All serum and urine parameters were
determined after a 12-h overnight fast.
Biochemical Assays
The content of Fe, Cu, Zn, Ca, and Mg in the serum and
urine samples was determined by the flame atomic absorp-
tion spectrometry (AAS-3 spectrometer, Carl Zeiss, Ger-
many with deuterium background correction). In order to
obtain concentrations of the serum bioelements, the samples
were diluted (v/v, 1:1) as follows: for Fe, Zn, and Cu
analyses 0.01 % Triton X-100 (Merck) was used, while for
the Mg and Ca analysis, aqueous solutions consisting of
0.01 % Triton X-100 (Merck) and 0.05 % lanthanum chlo-
ride (Merck) were used. The content of Fe, Cu, Zn, Ca, and
Mg in serum and urine samples was determined at the
following wavelengths: 248.3 nm (Fe), 324.8 nm (Cu),
213.9 nm (Zn), 422.7 nm (Ca), and 285.2 nm (Mg).
The accuracy of the method was verified using certified
reference materials (HUM ASY CONTROL 2 and URN
ASY CONTROL 2, Randox), and reached 95 %, 99 %,
94 %, 99 %, and 102 % for Ca, Mg, Fe, Zn, and Cu,
respectively [10].
Plasma TC, LDL-C, HDL-C, TG, and glucose levels
were measured using commercial kits. The accuracy and
precision of the techniques used to assay the lipids and
glucose were validated. Reproducibility was checked with
a human serum control (Randox). Accuracy was assessed by
means of the recovery value and its range between 95 % and
109 %, and the variability coefficient (an indicator of the
method’s precision) did not exceed 10 %.
The activity of glutathione peroxidase (GSH-Px) was
assayed in the erythrocyte hemolysate using a method of
Paglia and Valentine [11]. GSH-Px decomposes hydrogen
peroxide, causing oxidation of the reduced glutathione. Ox-
idized glutathione is then reduced in a reaction that is
catalyzed by glutathione reductase. The coenzyme of the
reaction is reduced nicotinamide adenine dinucleotide phos-
phate, which is transformed into oxidized form, and causes a
change in light absorbance at 340 nm (spectrophotometer
Sunrise, Tecan). Superoxide dismutase (SOD) activity was
determined in the erythrocyte hemolysate using a modifica-
tion of epinephrine-adenochrome detection system [12]. The
enzyme inhibits the reaction of adrenaline autooxidation to
adenochrome in an alkaline environment. The unit of SOD
activity under the given conditions is defined as the amount
of enzyme that inhibits 50 % of the reaction at the maximal
increase of absorbance rectilinear segment of adenochrome
formation at wavelength 450 nm (spectrophotometer Sun-
rise, Tecan). Erythrocyte GSH-Px and SOD activity was
determined using a commercial kit (Randox), and expressed
as units per gram of hemoglobin. The hemoglobin concen-
tration in milligrams per milliliters was determined using the
cyanmethemoglobin method [13].
Erythrocyte lysate was prepared from blood collected
with EDTA. Blood was centrifuged at 700–1,000×g at
4°C. Plasma was then removed. The red cells were washed
three times with cold isotonic saline solution. Erythrocytes
were lysed with a ninefold volume of ice-cold HPLC-grade
water, and then centrifuged at 10,000×g at 4°C. Supernatant
was used for assaying.
The concentration of ferritin in the serum was determined
by a two-site sandwich immunoassay using direct chemilu-
minometric technology (ADVIA Centaur XP analyzer),
which uses constant amounts of two anti-ferritin antibodies
[14].
The concentration of nitric oxide (NO) was determined
using the spectrophotometric method on the serum, with the
testing set by Oxis. The test determines nitric oxide concen-
tration based on the enzymatic conversion of nitrate to
nitrite by nitrate reductase. The reaction is followed by
colorimetric detection of nitrate as an azo dye product of
the Griess Reaction. The Griess reaction transforms nitrites
to NO, which then reacts with sulfanilic acid, and the
indirect product of the reaction interacts with N-(1-naphtyl)
ethylendiamine, leading to the formation of a red-violet
colored product having maximum absorbance at λ0
540 nm. The solution color change, measured spectropho-
tometrically (with Hyperion Micro Reader), is proportional
to the nitric oxide concentration [15].
Statistical Analysis
The experimental results were given as means±standard
deviation. The statistical analysis was carried out using
STATISTICA 7.0 software and the ANOVA test. A p value
less than 0.05 was considered statistically significant.
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Results
Body Mass Index and Blood Pressure
The results of BMI and blood pressure measurements are
presented in Table 1. No significant change was observed in
BMI or in the systolic or diastolic blood pressure of patients
during the study. However, the body mass index slightly
decreased after 6 weeks (38.43 vs. 37.93, p00.345) and
12 weeks (38.43 vs. 36.83, p00.204). Both systolic and
diastolic blood pressure did not change at all in comparison
with the baseline.
Biochemical Parameters
After 6 weeks of sibutramine treatment, a significant de-
crease was found only in TC (p00.031; Table 2). No change
in LDL-C, TG, glucose, or ferritin levels was observed at
6 weeks. After 12 weeks, a significant decrease was ob-
served for TC (p00.013), LDL-C (p00.034), TG (p0
0.044), glucose (p00.046), and ferritin (p00.030). GSH-
PX and SOD activity markedly increased (p00.036 and
p00.021, respectively) after 12 weeks of sibutramine treat-
ment. Serum levels of NO did not change during the study.
In women taking the placebo, no significant difference was
observed.
Minerals
A significant increase in Mg and Cu concentration was
observed in the serum of women with sibutramine after 6
(p00.037 and p00.029, respectively) and 12 weeks (p0
0.030 and p00.021, respectively; Table 3). It was also found
that Zn levels markedly decreased (p00.018) in serum after
12 weeks, and a slight decrease was also observed after
6 weeks of treatment. In the case of Fe serum concentration,
a slight decrease was found during the study.
The elimination of Ca, Mg, Fe, and Cu in urine declined
significantly at 6 weeks (p00.032, p00.048, p00.037, and
p00.026, respectively) and 12 weeks (p00.028, p00.031,
p00.023, and p00.018, respectively) of the study (Table 3).
The considerable decrease in Zn concentration in urine was
observed only after 12 weeks (p00.017), but a slight decline
in Zn elimination was evident after 6 weeks of the study.
It was found that the Ca/Mg and Zn/Cu molar ratios in
serum significantly decreased at the sixth (p00.042 and p0
0.032) and twelfth weeks (p00.034 and p00.021) of the
study (Table 4). A marked Cu/Fe molar ratio increase was
present at 6 (p00.035) and 12 weeks (p00.028) vs. the
baseline, and at 12 weeks vs. 6 weeks (p00.046). In urine,
significant increases in the molar ratios of Ca/Mg and Zn/
Cu, as well as a significant decrease in the Fe/Zn molar ratio
at 6 (p00.016, p00.027, and p00.041, respectively) and
12 weeks (p00.013, p00.022, and p00.037, respectively)
of sibutramine treatment were observed. No marked differ-
ences in women receiving the placebo were found.
Discussion
Sibutramine hydrochloride monohydrate is a norepinephrine
and serotonin reuptake inhibitor approved for the long-term
management of obesity, in conjunction with a reduced cal-
orie diet and behavior modification in patients unable to lose
weight by means of diet and lifestyle changes alone. The
efficacy of sibutramine has been demonstrated in random-
ized trials in obese patients [16–18]. Furthermore, its favor-
able influence on the lipid profile and glucose concentration
has been shown in several studies [19–21]. In the study of
Tambascia et al. [22], sibutramine demonstrated efficacy in
Table 1 Baseline values
Baseline 6 weeks 12 weeks
Sibutramine Placebo Sibutramine Placebo Sibutramine Placebo
(N024) (N020) (N024) (N020) (N024) (N020)
N 24 20 – – – –
Sex [F] 24 20 – – – –
Age [years] 40.61±12.13 40.72±12.22 – – – –
Sibutramine [dose] 15 mg – 15 mg – 15 mg –
BMI [kg/m2] 38.43±8.54 38.03±5.76 37.93±7.54 37.55±6.21 36.83±7.35 37.31±4.83
SBP [mmHg] 133.52±10.44 131.82±8.37 133.18±12.42 132.87±8.91 133.57±9.74 132.38±8.31
DBP [mmHg] 85.53±5.22 85.77±5.42 85.68±5.61 85.73±5.34 85.42±4.81 85.74±4.11
Blood pressure and BMI changes at 6 and 12 weeks in the group during the study. Data are means±SD
mean the arithmetic mean, SD standard deviation, N number of subjects, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure
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reducing weight, insulin resistance, triglicerides, and uric
acid, but not glucose or cholesterol, in non-diabetic wom-
en. The results of our study after 6 weeks show a signif-
icant decrease only for TC. No change in LDL-C, TG,
glucose levels were observed at that time. After 12 weeks, a
significant decrease in TC, LDL-C, TG, and glucose was
observed.
Some authors suggest that the use of sibutramine could
raise blood pressure on account of its peripheral sympatho-
mimetic effect [23]. Contrarily, reports of other authors and
the results of our own study show no significant impact of
sibutramine on blood pressure or on NO concentration in
long-term or short-term treatment [3, 24]. It is suggested that
sibutramine elicits a central sympatholytic effect in the
brain, counteracting, at least in part, peripheral sympathetic
stimulation.
To the best of our knowledge, this is the first clinical
study investigating the effect of sibutramine on mineral
status in obese women. The results of the experimental
studies suggest the potential influence of sibutramine on
minerals. Emer et al. [25] found that a relatively high dose
of sibutramine resulted in significant increases in Fe and Zn
levels in the kidneys and in the adrenal glands in rats. The
results of our study show significant changes in mineral
levels of obese women treated with sibutramine.
The mechanism may be related to reduced energy intake
as an effect of sibutramine action. It has been demonstrated
that lower food intake leads to a lower supply of minerals
Table 2 Biochemical parameters in serum changes at 6 and 12 weeks during the study
Baseline 6 weeks 12 weeks
Sibutramine Placebo Sibutramine Placebo Sibutramine Placebo
(N024) (N020) (N024) (N020) (N024) (N020)
TC [mmol/l] 4.41±0.58 4.40 ±0.51 4.11±0.57a 4.38±0.56 4.08±0.58a 4.35±0.52
LDL-C [mmol/l] 2.56±0.48 2.55±0.51 2.35±0.46 2.52±0.49 2.28±0.42a 2.50±0.43
HDL-C [mmol/l] 1.25±0.24 1.28±0.21 1.26±0.25 1.28±0.23 1.25±0.26 1.26±0.21
TG [mmol/l] 1.37±0.37 1.35±0.38 1.21±0.36 1.30±0.30 1.15±0.35a 1.30±0.31
Glucose [mmol/l] 5.35±0.47 5.31±0.48 5.33±0.46 5.30±0.47 5.18±0.27a 5.30±0.50
Ferritin [μg/l] 91.12±40.42 91.25±41.22 78.15±41.39 88.11±40.08 65.51±38.50a 85.14±30.83
Nitric oxide (NO) [μmol/l] 10.60±3.01 10.67±2.67 10.83±3.08 10.57±2.68 10.67±2.99 10.60±2.68
Glutathione peroxidase [U/gHb] 15.62±6.30 15.68±7.11 18.26±8.23 16.15±7.83 19.52±8.45a 16.22±6.28
Superoxide dismutase [U/gHb] 2,570±692 2,582±5.82 2,853±576 2,637±583 3,554±723a 2,628±683
Data are means±SD
mean the arithmetic mean, SD standard deviation, N number of subjects, TC total cholesterol, LDL-C LDL cholesterol, HDL-C HDL cholesterol,
TG triglycerides
a Sibutramine group p<0.05 vs baseline
Table 3 Minerals in serum and
urine changes at 6 and 12 weeks
during the study
Data are means±SD
mean the arithmetic mean, SD
standard deviation, N number of
subjects
aSibutramine group p<0.05 vs
baseline
Baseline 6 weeks 12 weeks
Sibutramine Placebo Sibutramine Placebo Sibutramine Placebo
(N024) (N020) (N024) (N020) (N024) (N020)
Serum
Ca [mmol]l] 2.54±0.13 2.52±0.12 2.65±0.42 2.60±0.21 2.52±0.25 2.50±0.33
Mg [mmol/l] 0.80±0.07 0.83±0.07 0.93±0.06a 0.85±0.06 0.95±0.06a 0.88±0.25
Fe [μmol/l] 17.85±5.32 17.33±5.18 16.82±6.24 16.84±5.10 16.35±5.92 16.58±5.03
Zn [μmol/l] 12.42±2.42 12.04±2.80 11.48±2.38 11.96±2.81 10.51±2.58a 11.46±2.91
Cu [μmol/l] 13.61±1.81 13.03±1.71 14.94±1.78a 13.41±1.80 15.68±1.92a 13.63±1.21
Urine
Ca [mmol/l] 3.84±2.53 3.21±2.31 2.97±2.09a 3.25±2.30 2.89±2.35a 3.18±2.18
Mg [mmol/l] 5.84±2.42 5.50±2.80 3.25±1.78a 5.00±1.80 3.05±1.50a 4.58±2.91
Fe [μmol/l] 9.27±5.21 9.30±4.77 6.02±4.20a 8.50±4.18 5.78±3.84a 7.90±5.10
Zn [μmol/l] 9.38±3.58 9.40±3.37 8.46±4.21 8.98±4.80 7.78±3.80a 9.12±2.83
Cu [μmol/l] 1.02±0.51 1.11±0.68 0.68±0.34a 0.98±0.80 0.61±0.35a 1.08±0.56
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and reduced mineral status in the body. Acuirre et al. [26]
reported that a 1,000 kcal/day diet decreases the intake of
Fe, Zn, Cu, and Ca by 50 %, 30 %, 40 %, and 9 %,
respectively.
This weight-reducing diet led to a reduction of Fe status
in obese patients, as indicated by the decrease in serum
ferritin. In our study, a significant decrease in ferritin, with
a slight (but not significant) reduction in body mass, was
also observed, though only in the women taking sibutr-
amine, and not in the group administered the placebo.
However, in the present study, the decreased level of
ferritin is connected with increased GSH-Px and SOD level
in the blood, which suggests that the change in serum
ferritin level is also associated with a change in inflamma-
tion in the body of obese women during the sibutramine
treatment. Our results may be consistent with the observa-
tion of Zafon et al. [27], who claim that ferritin concentra-
tion in the obese is due to inflammation, rather than to the Fe
status of the body.
The excretion of minerals in the urine of the studied
subjects may be a reflection of a change in the mineral
status of the body. Changes in the excretion of minerals
are not uniform, as shown in Table 3. This is evidenced by
the change in molar ratios of elements in the excreted urine.
The molar ratios of minerals in the blood also changed. In
each tissue of the body, the ion balance is maintained and
remains constant. The evaluation of mineral status and min-
eral metabolism in the body is possible on the basis of the
proportions found to hold between different minerals. There
are synergistic and antagonistic relationships between the
minerals, which directly affect the metabolism of the body.
Keeping an appropriate balance between the elements is, in
many cases, more important than their normal levels in the
tissue. Changes in the ratio between minerals in tissues
indicate metabolic disorders in the body and/or interactions
between minerals. In the present study, following the
sibutramine treatment we observed a decrease in the Ca
level (though insignificant) and a higher concentration of
Mg in serum. Ca and Mg levels in the body are regulated by
a negative-feedback system, and through competition for
intestinal absorption and renal reabsorption. Ca and Mg also
compete for membrane binding sites within the cell. A lower
Ca/Mg ratio in the serum, and higher Ca/Mg ration in urine
is probably the result of the disturbed Mg status following
sibutramine treatment.
Slightly lower Fe and Zn levels, as well as higher Cu
concentrations, were found in the serum after 6 and 12 weeks
of the study vs. the baseline. These changes may indicate
interactions between the elements due to the use of sibutr-
amine. Known interactions of Ca–Mg and Fe–Zn–Cu can be
observed. The higher Cu/Fe ratio and lower Zn/Cu ratio in
the serum of patients after treatment may be affected by a
disturbed Zn status. Decreasing the Zn level in the organism
increases the Cu level, which is a result of the Zn–Cu
antagonism.
In other studies, low plasma Zn levels were observed in
obese [28], and obese type-2 diabetic individuals [29]. Sim-
ilarly, rather low plasma Zn level was observed in obese
women in the current study. In some studies based on
hypocaloric diets and physical activity, weight loss in obese
women was associated with increased plasma Zn, and this
increase was not a reflection of diet [28]. In this study, we
observed an inverse relationship. Moreover, Konukoglua et
al. [29] found negative correlations between leptin and Zn in
serum among obese diabetic subjects. The results obtained
in our study may indicate the effects of sibutramine, but not
of weight loss or leptin concentration decrease (not analyzed
in this study), on changes in the Zn concentration in the
serum of obese women. It has been shown that Zn may
contribute to the modulation of serotonin uptake in the brain
[30]. Sibutramine is a serotonin uptake inhibitor, and so
sibutramine by influencing serotonin metabolism might also
Table 4 Mineral molar ratio in
serum and urine changes at 6 and
12 weeks during the study
Data are means±SD
mean the arithmetic mean, SD






Baseline 6 weeks 12 weeks
Sibutramine Placebo Sibutramine Placebo Sibutramine Placebo
(N024) (N020) (N024) (N020) (N024) (N020)
Serum
Ca/Mg 3.16±0.21 3.04±0.20 2.85±0.27a 3.06±0.25 2.66±0.23a 2.84±0.20
Fe/Zn 1.44±0.12 1.44 0±.13 1.47±0.12 1.41±0.14 1.56±0.12 1.45±0.10
Cu/Fe 0.76±0.09 0.75±0.10 0.89±0.05a 0.80±0.04 0.96±0.05a,b 0.82±0.07
Zn/Cu 0.92±0.11 0.92±0.12 0.77±0.12a 0.89±0.18 0.66±0.12a 0.86±0.09
Urine
Ca/Mg 0.65±0.23 0.59±0.25 0.92±0.21a 0.65±0.25 0.95±0.21a 0.69±0.31
Fe/Zn 0.98±0.31a 0.98±0.30 0.72±0.30a 0.95±0.31 0.74±0.31a 0.87±0.40
Cu/Fe 0.11±0.05 0.12±0.06 0.11±0.04 0.12±0.06 0.11±0.04 0.13±0.07
Zn/Cu 9.20±3.78a 8.47±3.05 12.5±4.65a 9.16±5.08 12.8±5.33a 8.45±3.08
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indirectly disturb the Zn status of the body. The influence of
sibutramine on neurotransmitters may also indirectly affect
the level of Cu in the body. It has been found that Cu
metabolism is associated with neurological functions (and
with the level of serotonin in the brain) [31, 32]. Moreover,
Lima et al. did not report any differences in Cu concentra-
tion in serum or erythrocytes when comparing obese and
non-obese female children [33]. In the present study we
observed that, along with the decrease in the concentration
of TG and TC, the levels of Fe and Zn lowered significantly,
while level of Cu in the serum increased. The results are
consistent with the data from our previous study, where
obese patients with hypertension and insulin resistance were
studied [34].
Treatment with sibutramine resulted in increase in GSH-
Px and SOD activity in the serum. GSH-Px is the main
enzyme of the enzymatic antioxidant defense system re-
sponsible for protecting against increases in ROS produc-
tion [35]. Hydrogen peroxide, formed by the catalytic
reaction of SOD, is both a reactive form of oxygen and a
normal cellular metabolite, and it is further detoxified by
GSH-Px and catalase [36]. The erythrocyte is a relatively
abundant focus of both free-radical-mediated injury by vir-
tue of enhanced endogenous rates of production of ROS and
impairment of tissue-free radical defense mechanisms [37,
38]. In addition, GSH is the substrate of GSH-Px, and the
cysteine derivative GSH is synthesized in erythrocytes, and
glutathione disulfide transported outside the cell to maintain
a high GSH/GSSG ratio [35, 38]. Disulfide-exchange reac-
tions occur between protein thiols and low molecular weight
disulfides [36]. In our present study, GSH-Px and SOD
activities in erythrocytes increased in the treatment groups
after the twelfth week. The observed changes may result
from an alternation of mineral concentrations during sibutr-
amine treatment. This possible relation was reported by
Vivoli et al., who found a positive relationship between
serum Cu and Cu–Zn SOD [39]. Moreover Piorunska-
Stoltzman et al. [40] reported a positive correlation between
Cu and GSH-Px in serum. The increase of erythrocyte
GSH-Px and SOD values in patients during sibutramine
treatments has also been attributed to the inhibition of free
oxygen radicals and lipid peroxidation [41], and the protec-
tive effects of sibutramine supplementation on glucose-6-
phosphate dehydrogenase activity in erythrocytes.
Our study has some limitations, for example short treat-
ment and the relatively small group of subjects. These
limitations result from group selection procedure, requiring
women without chronic diseases and not using additional
drugs. Moreover, this study was interrupted by the with-
drawal of sibutramine license in the EU. Finally, based on
these results and the literature data, it is difficult to explain
the precise mechanism of the mineral changes in the serum
and urine during sibutamine treatment. A better
understanding of this mechanism requires further extensive
biochemical studies.
Conclusion
Sibutramine favorably influences the lipid profile and glu-
cose concentration in obese women. Additionally, treatment
with sibutramine is associated with increase in GSH-Px and
SOD activity. However, 12-week sibutramine therapy
decreases Zn and increases Mg concentrations in the serum,
leading to mineral imbalances in obese women. The control
of minerals levels, particularly of Zn, and the potential need
for further supplementation should be considered in patients
treated with sibutramine.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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